Market closedNon-fractional
Blueprint Medicines/BPMC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Ticker
BPMC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
645
Website
www.blueprintmedicines.com
BPMC Metrics
BasicAdvanced
$7.1B
Market cap
-
P/E ratio
-$4.73
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$7.1B
Beta
0.65
Financial strength
Current ratio
3.759
Quick ratio
3.427
Long term debt to equity
164.405
Total debt to equity
192.455
Interest coverage (TTM)
-9.69%
Management effectiveness
Return on assets (TTM)
-24.40%
Return on equity (TTM)
-79.53%
Valuation
Price to revenue (TTM)
24.543
Price to book
22.77
Price to tangible book (TTM)
22.77
Price to free cash flow (TTM)
-16.108
Growth
Revenue change (TTM)
37.94%
Earnings per share change (TTM)
-51.26%
3-year revenue growth (CAGR)
-29.61%
3-year earnings per share growth (CAGR)
-5.77%
What the Analysts think about BPMC
Analyst Ratings
Majority rating from 18 analysts.
BPMC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$96M
33.66%
Net income
$89M
-180.34%
Profit margin
92.71%
-160.11%
BPMC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.19
-$2.20
-$1.82
-$1.32
-
Expected
-$2.54
-$2.37
-$2.04
-$1.66
-$1.29
Surprise
-13.77%
-7.06%
-10.78%
-20.59%
-
BPMC News
AllArticlesVideos
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
Accesswire·5 hours ago
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
Accesswire·1 day ago
Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Blueprint Medicines stock?
Blueprint Medicines (BPMC) has a market cap of $7.1B as of July 27, 2024.
What is the P/E ratio for Blueprint Medicines stock?
The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of July 27, 2024.
Does Blueprint Medicines stock pay dividends?
No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Blueprint Medicines dividend payment date?
Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.
What is the beta indicator for Blueprint Medicines?
Blueprint Medicines (BPMC) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Blueprint Medicines stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.